Daewoong Pharmaceutical, New Botulinum Strain Received

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 24th that it has completed the domestic import procedures by receiving the newly purchased Hall A Hyper botulinum strain from the United States at its facility.

Daewoong Pharmaceutical stated, "The receipt of the new strain was carried out in compliance with relevant laws and procedures in both the United States and Korea." They emphasized, "Contrary to the preliminary decision of the U.S. International Trade Commission (ITC) that obtaining and importing the strain into Korea was impossible, no issues occurred during government approval and delivery processes."

The company said that no other company is known to have clearly proven the origin of the strain. Daewoong Pharmaceutical explained, "Allergan refused the ITC's request to submit the strain and technology, and Ipsen, Merz, and Lanzhou Institute did not disclose the origin and acquisition process of their strains. Medytox claims to possess the Hall A Hyper strain brought to Korea in the 1970s by Yang Kyu-hwan from the University of Wisconsin in the U.S., but has not presented any proof documents."

They added, "Daewoong Pharmaceutical now holds two legitimate type A strains: the existing strain and the Hall A Hyper strain purchased from the U.S. We will continue the Nabota business stably in both aesthetic and therapeutic fields using the newly introduced strain regardless of the ITC's final ruling."